

PREPARATION OF *ENT*-3 β -HYDROXYKAUR-6,16-DIENE AND ITS MICROBIOLOGICAL TRANSFORMATION BY *GIBBERELLA FUJIKUROI*

CARMEN E. DIAZ, BRAULIO M. FRAGA and MELCHOR G. HERNANDEZ

Instituto de Productos Naturales Orgánicos, C.S.I.C., La Laguna, 38206-Tenerife, Canary Islands, Spain

(Received in revised form 20 August 1988)

Key Word Index—*Gibberella fujikuroi*, gibberellins, kaurenolides, *ent*-3 β -hydroxykaur-6,16-diene, linearol

Abstract—The microbiological transformation of *ent*-3 β -hydroxykaur-6,16-diene into *ent*-6 α ,7 α -epoxy-3 β -hydroxykaur-16-ene has been carried out. The substrate incubated was synthesized from the diterpene linearol.

INTRODUCTION


In the past few years we have studied the microbiological transformation of *ent*-kaurene diterpenes by *Gibberella fujikuroi* [1–6]. The purpose of these works was to obtain gibberellin analogues and to define the substrate requirements of the enzymes that participate in various biosynthetic steps in the gibberellin and kaurenolide pathway in this fungus. Continuing these studies we present here the results obtained in the chemical preparation and microbiological incubation of *ent*-3 β -hydroxykaur-6,16-diene (**1**) with *G. fujikuroi*.

RESULTS AND DISCUSSION


The substrate **1** was prepared in the following way. Partial acetylation of linearol (**2**) [7] gave the triacetate **3** and the diacetates **4** and **5**. The 3 α ,18-diacetate **4** was treated with tosyl chloride in pyridine to afford the corresponding tosylate **6**. Treatment of this derivative under reflux with collidine formed compound **7**, which was then hydrolysed to give *ent*-3 β ,18-dihydroxykaur-6,16-diene (**8**) [5]. Partial acetylation of this diene afforded the two monoacetates, **9** and **10**, and the diacetate **7**. Additional quantities of compound **9** were obtained by transacetylation of **10**. Treatment of the 3 α -monoacetate **9** with triphenylphosphine–carbon tetrachloride gave the chloride derivative **11**, reduction of which with tri-*n*-butyl tin hydride and subsequent hydrolysis of the acetate **12** formed, yielded *ent*-3 β -hydroxykaur-6,16-diene (**1**).

When compound **1** was incubated with the fungus *G. fujikuroi*, in the presence of AMO-1618, which blocks the formation of endogenous *ent*-kaur-16-ene [8, 9], *ent*-3 β -hydroxy-6 α ,7 α -epoxykaur-16-ene (**13**) was obtained by epoxidation of the 6,7 double bond. However, we were unable to detect any kaurenolide or gibberellin. The structure of the epoxide **13** followed from its ^1H NMR spectrum, in which the geminal hydrogens to the oxirane ring appear at δ 2.91 (*d*, *J* = 4 Hz) and 3.08 (*dd*, *J* = 2.5 and 4 Hz). The ^{13}C NMR spectrum of **13** also confirmed its structure; the spectrum is summarized in Table 1 together with that of the parent compound **14**. The H-5, H-6 coupling of 2.5 Hz is in accordance with a β -epoxide [5, 10]. The result of the incubation confirms that a 3 α -hydroxyl group in the kaur-16-ene derivatives inhibits their hydroxylation at C-19 by *G. fujikuroi* [3].


It has been suggested that the microbiological epoxidation of an alkene is sometimes equivalent to the hydroxylation of the corresponding alkane [11, 12]. Thus, in a previous work we have shown that *ent*-3 β ,18-dihydroxykaur-6,16-diene (**8**) is transformed into the epoxide **14** [4, 5], and *ent*-3 β ,18-dihydroxykaur-16-ene (**15**) is converted into the corresponding triol **16** [3]. On the other hand, in a previous work we have also shown that *ent*-3 β -hydroxykaur-16-ene (**17**) is not transformed




- 1** $\text{R}^1 = \text{R}^2 = \text{H}$
7 $\text{R}^1 = \text{Ac}, \text{R}^2 = \text{OAc}$
8 $\text{R}^1 = \text{H}, \text{R}^2 = \text{OH}$
9 $\text{R}^1 = \text{Ac}, \text{R}^2 = \text{OH}$
10 $\text{R}^1 = \text{H}, \text{R}^2 = \text{OAc}$
11 $\text{R}^1 = \text{Ac}, \text{R}^2 = \text{Cl}$
12 $\text{R}^1 = \text{Ac}, \text{R}^2 = \text{H}$




- 2** $\text{R}^1 = \text{R}^2 = \text{H}$
3 $\text{R}^1 = \text{R}^2 = \text{Ac}$
4 $\text{R}^1 = \text{Ac}, \text{R}^2 = \text{H}$
5 $\text{R}^1 = \text{H}, \text{R}^2 = \text{Ac}$
6 $\text{R}^1 = \text{Ac}, \text{R}^2 = \text{Ts}$



- 13** $\text{R}^1 = \text{OH}, \text{R}^2 = \text{H}$
14 $\text{R}^1 = \text{R}^2 = \text{OH}$



- 15** $\text{R} = \text{H}$
16 $\text{R} = \text{OH}$



- 17** $\text{R} = \text{H}$
18 $\text{R} = \text{OH}$

Table 1 ^{13}C NMR spectral data of compounds **13** and **14** (50 MHz)

C	13	14	C	13	14
1	39.50	39.50	11	16.51	16.51
2	27.40	26.73	12	33.24	33.12
3	78.95	76.41	13	42.30	42.24
4	38.71	41.88	14	36.34	35.87
5	55.89	51.08	15	45.93	45.85
6	53.70	53.23	16	154.69	154.56
7	60.81	60.75	17	104.78	104.88
8	42.95	42.83	18	28.00	71.13
9	50.94	50.69	19	16.28	11.73
10	37.91	37.64	20	19.59	19.88

by the fungus into the 7β -hydroxy analogue **18** [3]. In contrast we now report that the corresponding dehydro-derivative, *ent*-3 β -hydroxykaur-6,16-diene (**1**), is transformed into the $6\beta,7\beta$ -epoxide **13**. Therefore, it appears unlikely that the same enzymes are involved in 7β -hydroxylation and $6\beta,7\beta$ -epoxidation of *ent*-3 β -hydroxykaur-16-ene analogues. However, there is still insufficient evidence to exclude this possibility in the gibberellin and kaurenolide biosynthetic pathways.

EXPERIMENTAL

Mps uncorr., IR CHCl_3 , NMR CDCl_3 , MS 70 eV (probe). CC was performed on silica gel 0.063–0.2 mm. Substances were crystallized from petrol–EtOAc except where otherwise indicated.

Partial acetylation of linearol (*ent*-18-acetoxy-3 $\beta,7\alpha$ -dihydroxykaur-16-ene) Compound **2** [7] (1.1 g) in pyridine (15 ml) was treated with Ac_2O at 0° for 4 hr. Usual work-up and chromatography of the residue, eluting with petrol–EtOAc (4:1), afforded the triacetate of foliol (**3**) (60 mg), the diacetates **4** and **5**, 800 and 150 mg, respectively, and starting material (130 mg) *ent*-3 $\beta,18$ -diacetoxy-7 α -hydroxykaur-16-ene (**4**). Mp $210\text{--}213^\circ$, ^1H NMR (90 MHz) δ 0.81 and 1.07 (each 3H, s), 2.01 and 2.03 (each 3H, s), 3.58 (1H, *br* s, H-7), 3.52 and 4.05 (each 1H, *d*, $J = 12$ Hz, H-18), 4.82 (3H, *br*, H-3 and H-17), EIMS m/z (rel. int.) 404 [$\text{M}]^+$ (1), 386 (1), 344 (1), 326 (20), 298 (1), 284 (6), 266 (34), 253 (21), 251 (22). *ent*-7 $\alpha,18$ -diacetoxy-3 β -hydroxykaur-16-ene (**5**). Mp $169\text{--}171^\circ$, ^1H NMR (90 MHz) δ 0.76 and 1.09 (each 3H, s), 2.07 and 2.09 (each 3H, s), 3.68 (1H, *br* s, H-3), 3.58 and 4.38 (each 1H, *d*, $J = 12$ Hz, H-18), 4.85 (3H, *br*, H-7 and H-17), EIMS m/z (rel. int.) 344 [$\text{M} - \text{EtOAc}]^+$ (1), 326 (12), 248 (8), 266 (16), 253 (14), 251 (7), 225 (6), 199 (7), 197 (5), 185 (12), 171 (6), 157 (6), 149 (17).

Tosylation of 4, *ent*-3 $\beta,18$ -diacetoxy-7 α -hydroxykaur-16-ene (**4**) (800 mg) in dry pyridine (10 ml) was treated with tosyl chloride (2.5 g) at room temp for 5 days. Usual work-up afforded **6**, mp $164\text{--}165^\circ$, ^1H NMR (60 MHz) δ 0.80 and 1.07 (each 3H, s), 2.00 and 2.14 (each 3H, s), 2.45 (each 3H, s), 3.48 and 3.88 (each 1H, *d*, $J = 12$ Hz, H-18), 4.75 (1H, *br* s, H-7), 4.80 (3H, *br*, H-3 and H-17), 7.35 and 7.80 (each 2H, *d*, $J = 9$ Hz), EIMS m/z (rel. int.) 386 [$\text{M} - \text{TsOH}]^+$ (2), 326 (6), 266 (72), 251 (37), 238 (15), 223 (14), 209 (7), 195 (7), 172 (34), 169 (9), 157 (12), 155 (8), 143 (11), 131 (9).

ent-3 $\beta,18$ -diacetoxykaur-6,16-diene (**7**). The tosylate **6**, obtained above, in collidine (10 ml) was refluxed for 30 min. Usual work-up gave **7** (710 mg), ^1H NMR (60 MHz) δ 0.88 and 1.01

(each 3H, s), 2.04 (6H, s), 3.85 (2H, s, H-18), 4.88 (3H, *br*, H-3 and H-17), 5.55 (2H, s, H-6 and H-7), EIMS m/z (rel. int.) 326 [$\text{M} - \text{HOAc}]^+$ (1), 311 (1), 284 (2), 266 (64), 251 (100), 223 (16), 195 (11).

Hydrolysis of 7. The diacetate **7** (700 mg) in MeOH was treated with MeOH–KOH (5%) (15 ml) at room temp for 24 hr. Usual work-up gave **8**, mp $140\text{--}142^\circ$, [$\text{M}]^+$ at m/z 302.2253. $\text{C}_{20}\text{H}_{30}\text{O}_2$ requires 302.2245, ^1H NMR (90 MHz) δ 0.90 and 0.99 (each 3H, s), 3.40 and 3.72 (each 1H, *d*, $J = 11$ Hz, H-18), 3.60 (1H, *br*, H-3), 4.80 (2H, *br* s, H-17), 5.45 (1H, s, H-6 and H-7), EIMS m/z (rel. int.) 302 [$\text{M}]^+$ (5), 284 (26), 269 (100), 266 (10), 251 (16), 241 (10), 223 (25), 211 (38), 209 (8), 199 (15).

Partial acetylation of 8. Compound **8** (2 g) in pyridine (15 ml) was treated with Ac_2O at 0° for 2.5 hr. Usual work-up and chromatography of the residue, eluting with petrol–EtOAc, afforded **7** (650 mg). Further elution gave *ent*-3 β -acetoxy-18-hydroxykaur-6,16-diene (**9**) (200 mg), mp $108\text{--}110^\circ$, [$\text{M} - \text{HOAc} - \text{Me}]^+$ at 269.1853. $\text{C}_{19}\text{H}_{28}\text{O}$ requires 269.1905, ^1H NMR (90 MHz) δ 0.73 and 1.03 (each 3H, s), 2.02 (3H, s), 3.01 and 3.48 (each 1H, *d*, $J = 12$ Hz, H-18), 4.90 (2H, *br*, H-17), 4.98 (1H, *t*, H-3), 5.57 (2H, s, H-6 and H-7), EIMS m/z (rel. int.) 284 [$\text{M} - \text{HOAc}]^+$ (13), 269 (64), 266 (40), 251 (72), 223 (17), 211 (24), 199 (30), 195 (11), 183 (19). Further elution gave *ent*-3 β -hydroxy-18-acetoxykaur-6,16-diene (**10**) (1.2 g), mp $131\text{--}133^\circ$, [$\text{M} - \text{HOAc} - \text{Me}]^+$ at 269.1904. $\text{C}_{19}\text{H}_{28}\text{O}$ requires 269.1905, ^1H NMR (90 MHz) δ 0.93 and 1.00 (each 3H, s), 2.11 (3H, s), 3.48 (1H, *br*, H-3), 3.81 and 4.29 (each 1H, *d*, $J = 12$ Hz, H-18), 4.48 (2H, *br*, H-17), 5.55 (2H, s, H-6 and H-7), EIMS m/z (rel. int.) 284 [$\text{M} - \text{HOAc}]^+$ (8), 269 (30), 266 (21), 251 (11), 223 (10), 211 (13), 199 (16), 195 (9), 183 (12).

Transacetylation of 10. Compound **10** (1.2 g) in CHCl_3 (20 ml) was treated with concd HCl (two drops) at room temp for 5 hr. Neutralization with NaHCO_3 , extraction with EtOAc and chromatography of the residue, eluting with petrol–EtOAc (5:1), gave **10** (450 mg), a mixture of **9** and **10** (300 mg) and **9** (280 mg).

ent-3 β -Acetoxy-18-chlorokaur-6,16-diene (**11**). To the monoacetate **9** (450 mg) in dry pyridine (7 ml) and CCl_4 (15 ml) triphenylphosphine (1 g) was added and the mixt. refluxed for 2 hr. Extraction with EtOAc in the usual way and chromatography of the residue, eluting with petrol–EtOAc, afforded compound **11** (460 mg), mp $117\text{--}119^\circ$, [$\text{M}]^+$ at 362.1995. $\text{C}_{22}\text{H}_{31}\text{O}_2\text{Cl}$ requires 362.1013, ^1H NMR (60 MHz) δ 0.93 and 1.01 (each 3H, s), 2.02 (3H, s), 3.42 (2H, *br* s, H-18), 4.85 (2H, *br*, H-17), 5.03 (1H, *t*, H-3), 5.49 (2H, *br* s, H-6 and H-7), EIMS m/z (rel. int.) 362 [$\text{M}]^+$ (18), 347 (5), 319 (22), 302 (7), 291 (21), 287 (92), 267 (34), 253 (28), 225 (11), 211 (16), 199 (100).

Reduction of 11. Compound (**11**) (460 mg) in dry toluene (8 ml) was added dropwise to a refluxing soln of tri-*n*-butyl tin hydride (0.5 ml) and azobisisobutyronitrile (trace) in dry toluene (5 ml). The mixt. was allowed to reflux for a further 18 hr when the solvent was evapd and the residue dissolved in Et_2O . An aq. soln of KF was added and the ppt. sepd by filtration. The ether fraction was dried (Na_2SO_4) and the solvent evapd. Chromatography of the residue, eluting with petrol–EtOAc (9:1) afforded *ent*-3 β -acetoxykaur-6,16-diene (**12**) (320 mg), mp $124\text{--}126^\circ$, [$\text{M}]^+$ at 328.2397. $\text{C}_{22}\text{H}_{32}\text{O}_2$ requires 328.2402, ^1H NMR (60 MHz) δ 0.88 (6H, s), 0.97 (3H, s), 2.03 (3H, s), 4.52 (1H, *m*, H-3), 4.82 (2H, *br*, H-17), 5.53 (2H, *br* s, H-6 and H-7), EIMS m/z (rel. int.) 328 [$\text{M}]^+$ (20), 269 (34), 268 (22), 253 (100), 225 (46), 211 (13), 199 (100).

Hydrolysis of 12. The monoacetate **12** was treated as described above for **7** giving *ent*-3 β -hydroxykaur-6,16-diene (**1**), mp $171\text{--}173^\circ$ (from MeOH–EtOAc), [$\text{M}]^+$ at 286.2321. $\text{C}_{20}\text{H}_{30}\text{O}$ requires 286.2297, ^1H NMR (200 MHz) δ 0.73, 0.96 and 1.01 (each 3H, s), 3.25 (1H, *m*, H-3), 4.83 (2H, *br* s, H-17), 5.43 (1H, *dd*, $J = 3$ and 11 Hz, H-6), 5.63 (1H, *d*, $J = 11$ Hz, H-7), EIMS m/z (rel.

int.) 286 [M]⁺ (27), 271 (8), 253 (80), 225 (24), 215 (13), 199 (68), 197 (14), 185 (25), 183 (13)

Incubation expt *G. fujikuroi* (ACC 917), inhibited with 5×10^{-5} AMO 1618, was grown in shake cultures at 25° for 1 day in 75 conical flasks (250 ml), each containing sterile medium (50 ml) *ent*-3 β -Hydroxykaur-6,16-diene (1) (200 mg) in EtOH (30 ml) was distributed equally among the flasks and the incubation allowed to continue for a further 5 days. The broth was then filtered, adjusted to pH 2 with dil HCl and extracted with EtOAc. The mycelium was treated with liquid N₂, crushed with a mortar and extracted with EtOAc. The two extracts were combined and sepd into acidic and neutral fractions with NaHCO₃. The neutral fraction was chromatographed on silica gel. Elution with petrol-EtOAc gave starting material (50 mg) and *ent*-6 α ,7 α -epoxy-3 β -hydroxykaur-16-ene (13) (27 mg), mp 181–183°, [M]⁺ at 302.2245 C₂₀H₃₀O₂ requires 302.2244, ¹H NMR (200 MHz) δ 0.92, 0.98 and 1.13 (each 3H, s), 2.91 (1H, d, *J* = 4 Hz, H-7), 3.08 (1H, dd, *J* = 2.5 and 4 Hz, H-6), 3.24 (1H, t, H-3), 4.84 (2H, br s, H-17), EIMS *m/z* (rel. int.) 302 [M]⁺ (3), 287 (6), 284 (5), 269 (13), 243 (7), 241 (10), 236 (9), 227 (8), 199 (8), 189 (15).

Acknowledgements—We thank Prof B Rodriguez (Instituto de Química Orgánica, CSIC., Madrid) and Dr A García-Granados (Universidad de Granada) for samples of linearol, and

Dr J. R. Hanson for gifts of *G. fujikuroi*. This work was supported by a grant from the C A I C Y T (Madrid).

REFERENCES

- 1 Fraga, B. M., Hanson, J. R. and Hernandez, M. G. (1978) *Phytochemistry* **17**, 812.
- 2 Fraga, B. M., Hanson, J. R., Hernandez, M. G. and Sarah, F. Y. (1980) *Phytochemistry* **19**, 1087.
- 3 Fraga, B. M., Gonzalez, A. G., Hanson, J. R., Hernandez, M. G. (1981) *Phytochemistry* **20**, 57.
- 4 Fraga, B. M., Gonzalez, A. G., Gonzalez, P., Hanson, J. R., Hernandez, M. G. and Hitchcock, P. B. (1982) *J. Chem. Soc., Chem. Commun.* 311.
- 5 Fraga, B. M., Gonzalez, A. G., Gonzalez, P., Hanson, J. R., and Hernandez, M. G. (1983) *Phytochemistry* **22**, 691.
- 6 Fraga, B. M., Gonzalez, P., Hernandez, M. G., Perales, A. and Tellado, F. G. (1986) *Phytochemistry* **25**, 1235.
- 7 Quesada, T. G., Rodriguez, B. and Valverde, S. (1972) *Tetrahedron Letters* 2187.
- 8 Cross, B. E. and Myers, P. L. (1969) *Phytochemistry* **8**, 79.
- 9 Barnes, M. F., Light, E. N. and Lang, A. (1969) *Planta* **88**, 172.
- 10 Hanson, J. R. and Hawker, J. (1972) *Tetrahedron* **28**, 2521.
- 11 Bloom, B. M. and Shull, G. M. (1955) *J. Am. Chem. Soc.* **77**, 5767.
- 12 Gelb, M. H., Malkonen, P. and Sligar, S. G. (1982) *Biochem. Biophys. Res. Commun.* **104**, 853.